Loading animation
  • Home
  • About us View About us's child pages
    • Who we are
    • Our business model
    • Our strategy
    • Board of Directors
  • What we do View What we do's child pages
    • Our technology
    • Our product development pipeline
    • MED3000 View MED3000's child pages
      • MED3000 Overview
      • MED3000 Clinical Programme
      • MED3000 Commercial potential
    • TPR100 View TPR100's child pages
      • TPR100 Clinical Data
      • TPR100 Commercial potential
    • Other products View Other products's child pages
      • TIB200
      • CBD100
      • CSD500
    • Products FAQ's View Products FAQ's's child pages
      • DermaSys® FAQs
      • MED3000 FAQs
      • MED2005 FAQs
      • TPR100 FAQs
      • CBD100 FAQs
  • Investor centre View Investor centre's child pages
    • Share price chart
    • Corporate documentation
    • Videos and webcasts View Videos and webcasts's child pages
      • Videos
      • Webcasts
    • RNS
    • Alert service
    • Shareholder centre View Shareholder centre's child pages
      • Investor contacts and advisors
      • Shareholder information
      • Financial calendar
      • Investor FAQs
      • Analyst Research View Analyst Research's child pages
        • 2020
        • 2019
    • Corporate Governance
    • AIM rule 26
  • Media View Media's child pages
    • News
    • Event calendar
    • RNS
    • Videos
    • Alert service
  • Contact us

Please use the arrows to navigate to the sub pages

  • About us View About us's child pages

    About us

    Futura Medical is a pharmaceutical company developing a portfolio of innovative products based on our proprietary, transdermal DermaSys®  technology.

    Explore this section
    • Who we are
    • Our business model
    • Our strategy
    • Board of Directors
  • What we do View What we do's child pages

    What we do

    Futura Medical is developing a portfolio of innovative products for two large markets, sexual health and pain.

    Explore this section
    • Our technology
    • Our product development pipeline
    • MED3000 View MED3000's child pages

      MED3000

      • MED3000 Overview
      • MED3000 Clinical Programme
      • MED3000 Commercial potential
    • TPR100 View TPR100's child pages

      TPR100

      • TPR100 Clinical Data
      • TPR100 Commercial potential
    • Other products View Other products's child pages

      Other products

      • TIB200
      • CBD100
      • CSD500
    • Products FAQ's View Products FAQ's's child pages

      Products FAQ's

      • DermaSys® FAQs
      • MED3000 FAQs
      • MED2005 FAQs
      • TPR100 FAQs
      • CBD100 FAQs
  • Investor centre View Investor centre's child pages

    Investor centre

    Futura has a proven track record in delivery and completion of Research & Development projects up to value inflection points at which they are suitable for commercialisation partners.

    WEBCASTS

    Explore this section
    • Share price chart
    • Corporate documentation
    • Videos and webcasts View Videos and webcasts's child pages

      Videos and webcasts

      • Videos
      • Webcasts
    • RNS
    • Alert service
    • Shareholder centre View Shareholder centre's child pages

      Shareholder centre

      • Investor contacts and advisors
      • Shareholder information
      • Financial calendar
      • Investor FAQs
      • Analyst Research View Analyst Research's child pages
        • 2020
        • 2019
    • Corporate Governance
    • AIM rule 26
  • Media View Media's child pages

    Media

    This section contains the latest RNS, news and videos.

    Explore this section
    • News
    • Event calendar
    • RNS
    • Videos
    • Alert service
  • Contact us
  • About us View About us's child pages
    • Who we are
    • Our business model
    • Our strategy
    • Board of Directors
  • What we do View What we do's child pages
    • Our technology
    • Our product development pipeline
    • MED3000 View MED3000's child pages
      • MED3000 Overview
      • MED3000 Clinical Programme
      • MED3000 Commercial potential
    • TPR100 View TPR100's child pages
      • TPR100 Clinical Data
      • TPR100 Commercial potential
    • Other products View Other products's child pages
      • TIB200
      • CBD100
      • CSD500
    • Products FAQ's View Products FAQ's's child pages
      • DermaSys® FAQs
      • MED3000 FAQs
      • MED2005 FAQs
      • TPR100 FAQs
      • CBD100 FAQs
  • Investor centre View Investor centre's child pages
    • Share price chart
    • Corporate documentation
    • Videos and webcasts View Videos and webcasts's child pages
      • Videos
      • Webcasts
    • RNS
    • Alert service
    • Shareholder centre View Shareholder centre's child pages
      • Investor contacts and advisors
      • Shareholder information
      • Financial calendar
      • Investor FAQs
      • Analyst Research View Analyst Research's child pages
        • 2020
        • 2019
    • Corporate Governance
    • AIM rule 26
  • Media View Media's child pages
    • News
    • Event calendar
    • RNS
    • Videos
    • Alert service
  • Contact us
    Smiling couple hugging

    MED3000 FAQs

    • Home
    • What we do
    • Products FAQ's
    • MED3000 FAQs

    • What is MED3000?

      MED3000, our lead product, is a topical gel which utilises our proprietary technology DermaSys®, developed specifically for the treatment of erectile dysfunction (“ED”). MED3000 is a fast-acting topical treatment which has the potential to be a highly differentiated product by addressing significant unmet needs in the ED market.

    • What is the difference between MED2005 and MED3000?

      MED3000 is now the codename for a formulation of DermaSys® developed specifically for the treatment of ED. MED3000 is a unique formulation of DermaSys® using volatile solvent components tailored for the treatment of ED.

    • How does MED3000 work?

      MED3000 is a topical gel applied directly to the head (glans) of the penis for the treatment of ED.

      MED3000 works through an evaporative and unique mode of action.  MED3000’s combination of volatile solvent components creates an evaporative and novel action that stimulates nerve sensors in the highly innervated glans penis rapidly, leading to smooth muscle relaxation, tumescence and erection.

       

    • What is the regulatory pathway for a medical device? Why has Futura decided to go down this route?

      A medical device is described within the EU as a product which does not achieve its principal intended action on the human body by pharmacological, immunological or metabolic means.  

      These regulatory positions are the consensus from a number of regulatory experts consulted by Futura.  The Company is making progress with filing MED3000 for approval as a medical device in both Europe and the United States.

    • Can I request a sample of MED3000?

      Unfortunately, under the current regulations, Futura Medical are not able to provide samples.

    • When will MED3000 be on the market?

      In Europe the Company submitted the Technical Dossier on MED3000 for review to the designated European Notified Body as announced on 14th July 2020. [A Notified Body is an organisation designated by EU regulators to assess the conformity of medical devices before being placed on the market.] In parallel, as announced in February 2020, the Company had been progressing the development of its Quality Management System (QMS) and in early August received a positive audit opinion from the Company’s designated Notified Body. These milestones pave the way for the Notified Body to complete its review of MED3000 under the new European Medical Device Regulations. Futura continues to target a 2021 European approval date.

      The company has provided a regulatory update on 22nd October 2020.  In the USA, Futura has continued to work proactively with the FDA to confirm the design of the requested supplemental clinical trial to provide the necessary reassurance of MED3000's efficacy for up to six months.  The Company's previous 1,000 patient study (FM57), which reported results in December 2019, met all its primary endpoints against a pre-treatment baseline and across all ED severities for efficacy for up to three months and also provided extensive safety reassurance. In addition, progress has been made around the label and leaflet development to enable the product to be approved by the FDA without the need of a doctor's prescription.

       The Company is pleased to confirm that following its third pre-submission meeting with FDA, there was preliminary agreement on the design and scope of this small supplementary study, known as "FM71" subject to the issue of the final meeting minutes. The final study protocol can only be completed once the FDA minutes have been received. However, based on the pre-submission discussions FM71 is expected to be a comparative, randomised, open label, home use, parallel group study in approximately 100 patients with erectile dysfunction. Approximately 20 subjects will be located in the United States to provide reassurance that data generated outside the US is comparable to the US population. As an open-label design the study will be neither placebo controlled nor double-blinded, the study's primary endpoint will be to compare MED3000 against a pre-treatment baseline for efficacy for up to six months. The lowest "on demand" dose of tadalafil, 5mg (Cialis) will also be measured against pre-treatment baseline to enable the FDA to compare an overall risk/benefit analysis of the two treatments for the 6 month period of the study looking at efficacy, speed of onset and safety. 50 patients with ED will be included in each treatment arm of the study.

      Detailed planning for the study has now commenced and Futura is targeting Q1 2021 patient enrolment depending on completion of the final study protocol for FM71.

    • When will MED3000 regulatory filings for marketing authorisation be made in Europe and USA?

      In Europe the Company submitted the Technical Dossier on MED3000 for review to the designated European Notified Body as announced on 14th July 2020. [A Notified Body is an organisation designated by EU regulators to assess the conformity of medical devices before being placed on the market.] In parallel, as announced in February 2020, the Company had been progressing the development of its Quality Management System (QMS) and in early August received a positive audit opinion from the Company’s designated Notified Body. These milestones pave the way for the Notified Body to complete its review of MED3000 under the new European Medical Device Regulations. Futura continues to target a 2021 European approval date.

      In the USA, as per the update on 22nd October, Futura has continued to work proactively with the FDA to confirm the design of the requested supplemental clinical trial to provide the necessary reassurance of MED3000's efficacy for up to six months.  The Company's previous 1,000 patient study (FM57), which reported results in December 2019, met all its primary endpoints against a pre-treatment baseline and across all ED severities for efficacy for up to three months and also provided extensive safety reassurance. In addition, progress has been made around the label and leaflet development to enable the product to be approved by the FDA without the need of a doctor's prescription.

       The Company is pleased to confirm that following its third pre-submission meeting with FDA, there was preliminary agreement on the design and scope of this small supplementary study, known as "FM71" subject to the issue of the final meeting minutes. The final study protocol can only be completed once the FDA minutes have been received. However, based on the pre-submission discussions FM71 is expected to be a comparative, randomised, open label, home use, parallel group study in approximately 100 patients with erectile dysfunction. Approximately 20 subjects will be located in the United States to provide reassurance that data generated outside the US is comparable to the US population. As an open-label design the study will be neither placebo controlled nor double-blinded, the study's primary endpoint will be to compare MED3000 against a pre-treatment baseline for efficacy for up to six months. The lowest "on demand" dose of tadalafil, 5mg (Cialis) will also be measured against pre-treatment baseline to enable the FDA to compare an overall risk/benefit analysis of the two treatments for the 6 month period of the study looking at efficacy, speed of onset and safety. 50 patients with ED will be included in each treatment arm of the study.

      Detailed planning for the study has now commenced and Futura is targeting Q1 2021 patient enrolment depending on completion of the final study protocol for FM71.

    • Can I participate in the MED3000 clinical trial/Can I try this product?/Can I become a test patient? How can I apply for the clinical trial?

      Currently there are no requirements for patients in clinical trials however as per the regulatory update on 22nd October 2020, the Company is pleased to confirm that following its third pre-submission meeting with FDA, there was preliminary agreement on the design and scope of a small supplementary study, known as "FM71" subject to the issue of the final meeting minutes. Detailed planning for the study has now commenced and Futura is targeting Q1 2021 patient enrolment depending on completion of the final study protocol for FM71.

      Patients interested in participating will be able to find details in due course on clinicaltrials.gov.

    • Why wasn’t MED2005 effective against Placebo ?

      The DermaSys® control (now known as MED3000) showed very high levels of efficacy in mild, moderate and severe ED. The vast majority of subjects experienced a meaningful clinical improvement in their ED; up to 83%. This left limited ability to show additional improvement for MED2005.

    • Why was no significant difference shown as a result of the active, in any formulation?

      All four formulations tested; the Dermasys® control (now known as MED3000) and the 3 formulations containing the active ingredient in the Dermasys® base, showed very high levels of efficacy in mild, moderate and severe ED when compared to the pre-treatment (baseline) level of ED. However, because the vast majority of subjects experienced a meaningful clinical improvement, up to 83%, with the  Dermasys® control. This left limited ability to show additional improvement for MED2005.

    • Why did you use DermaSys® as a placebo?

      An ED-specific DermaSys® formulation (now known as MED3000) was used as a control arm (placebo) following regulatory requirements, including the FDA in the US. The documented code requirement here is that the placebo must be as identical as possible to the test product. With respect to physical characteristics, placebos must have identical smell, colour, physical sensation on the skin to enable studies to be authentically blinded, disabling the patient from determining which is the drug and which is the placebo. The FDA acknowledge that not all placebos are inactive and to meet their requirements it was agreed in consultation with them that only the DermaSys® base would be appropriate.

    • Did the Phase 2 results show placebo effect?

      The Phase 2 study did show a placebo effect which was expected as the massaging of gel into the glans penis will cause some sexual stimulation. However, the effect was much lower than experienced in the phase 3 study. We believe the greater effectiveness in the Phase 3 study is a result of two main factors.

      1. The study had far greater scale than the Phase 2 study. The study ran for 12 weeks versus 4 weeks where we noticed improvement in efficacy between 4 and 12 weeks. Also 61 sites were used versus 4 sites in the phase 2 study which would reduce the impact of natural variability occurring between test sites. Moreover, 3792 versus 984 intercourse attempts were made which is a much larger and more reliable sample size to study the effect.
      2. We learnt from the Phase 2 study that enhancements to the subject recruitment process and pre-screening were required and therefore much greater emphasis on this was placed in the Phase 3 study with very strict compliance to the inclusion and exclusion criteria. We also placed greater emphasis on patient training and therefore compliance to the treatment regimen.

      Therefore, we have concluded that in moving from a small Phase 2 study to a large Phase 3 study that the placebo effect was far greater than first indicated and presents an exciting opportunity in its own right without the inclusion of a drug substance.

    • When is Futura Medical looking to start the new clinical trial?

      As mentioned in the July 2020 RNS, the next steps will be to confirm design of the new clinical trial with FDA to provide the necessary reassurance of MED3000's efficacy for up to six months' and progress the OTC label and leaflet development.

      As per the Company’s regulatory update on 22nd October 2020, following Futura’s third pre-submission meeting with FDA, there was preliminary agreement on the design and scope of this small supplementary study, known as "FM71" subject to the issue of the final meeting minutes. The final study protocol can only be completed once the FDA minutes have been received. However, based on the pre-submission discussions FM71 is expected to be a comparative, randomised, open label, home use, parallel group study in approximately 100 patients with erectile dysfunction. Approximately 20 subjects will be located in the United States to provide reassurance that data generated outside the US is comparable to the US population. As an open-label design the study will be neither placebo controlled nor double-blinded, the study's primary endpoint will be to compare MED3000 against a pre-treatment baseline for efficacy for up to six months. The lowest "on demand" dose of tadalafil, 5mg (Cialis) will also be measured against pre-treatment baseline to enable the FDA to compare an overall risk/benefit analysis of the two treatments for the 6 month period of the study looking at efficacy, speed of onset and safety. 50 patients with ED will be included in each treatment arm of the study.

      Detailed planning for the study has now commenced and Futura is targeting Q1 2021 patient enrolment depending on completion of the final study protocol for FM71.

    You may also be interested in

    MED3000 Overview
    MED3000 Clinical Programme
    MED3000 Commercial potential
    Futura Medical logo

    ©2021 Futura Medical

    • Sitemap
    • Contact us
    • Accessibility
    • Terms of use
    • Privacy & cookies policies

    Designed and developed by
    jonesandpalmer.co.uk